Cefotaxime as the potential cause of transient acquired von Willebrand syndrome.
Acquired von Willebrand syndrome (AvWS) is a relatively rare bleeding disorder. It has been reported in association with myeloproliferative disorders, autoimmune diseases, plasma cell dyscrasias and certain drugs. Cefotaxime is a third generation cephalosporin widely used for surgical prophylaxis and as empirical treatment of bacterial meningitis. We report a case of a transient AvWS in association with cefotaxime therapy.
Haj
M A
MA
Haematology Department, Arthur Bloom Haemophilia Centre, University Hospital of Wales, Cardiff, UK. montaserhaj@yahoo.co.uk
Murch
N
N
Bowen
D J
DJ
Sati
H I
HI
Beddal
A
A
Benton
A
A
Collins
P
P
D000328:Adult; D002439:Cefotaxime / Q000009:adverse effects* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D016896:Treatment Outcome; D014842:von Willebrand Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy
D002439:Cefotaxime